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SUMMARY  
The American Cancer Society expects that there will be more than 20,000 new cases of multiple 
myeloma (MM) in the US in 2011 and despite the new treatments now available, the median 
survival rate is only 5 years.  Galectin-3C (Gal-3C) is a human lectin involved in cellular 
processes including cellular differentiation, apoptosis, neoplastic transformation, and metastasis.  
Gal-3C contains the carbohydrate recognition domain (CRD) of galectin-3 and is thought to act 
as a dominant negative inhibitor of galectin-3-mediated cross-linking.  Gal-3C is a proprietary 
truncated, inhibitory form of galectin-3.  Results showed that in a subcutaneous U266 cell 
NOD/SCID mouse model of human MM, treatment with an N-terminally truncated form of 
galectin-3, termed Gal-3C significantly inhibited tumor growth.  Furthermore, in vitro data 
indicated that Gal-3C acts by inhibition of angiogenesis, MM cell migration and invasion, and 
NF-kB activation. Moreover, Gal-3C facilitates the antitumor activity of bortezomib, a 
proteasome inhibitor for MM treatment. Gal-3C and bortezomib also synergistically inhibited 
MM-induced angiogenesis activity in vitro. The delivery of Gal-3C to patients will be via a 
pump during initial clinical trials.  In the long-term, the plan is to develop a formulation of Gal-
3C for sustained release to increase survival for patients with MM.   
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1.  INTRODUCTION 
 
1.1 MULTIPLE MYELOMA 
Multiple myeloma (MM) is a malignancy caused by clonal proliferation and accumulation of 
terminally differentiated B plasma cells (PCs) that accumulate in the bone tissue, causing bone 
destruction and interference with normal PC activity by altered PCs that generate non-specific 
monoclonal Igs called the “M-protein” [1]. 
MM is always preceded by a premalignant stage called monoclonal gammopathy of unknown 
significance (MGUS) [2]. Initially, MM is a slowly proliferating tumor. Less than 1% of MM 
cells synthesize DNA until the very late stages of the disease [3] when the cells are found 
outside the bone marrow (BM) in extramedullary locations including peripheral blood, pleural 
effusion, and ascites [4]. MM inevitably spreads to involve the entire BM causing death.  
MM symptoms include dysregulation of calcium, renal failure, anemia, and bone lesions. MM 
is diagnosed by blood and urine tests, and in advanced disease skeletal surveys are used for 
bone assessment. A staging system is based on serum levels of calcium, creatinine, hemoglobin, 
M-protein, and most significantly, serum albumin and b2-microglobulin (b2m). Median survival 
in stage I is 62 months, in stages II and III, 45 and 29 months, respectively [5,6]. 
The development of cytogenetic, genomic, and proteomic markers for MM [7-15] are expected 
to lead to new targeted therapeutics and rational drug combinations.  
Chemotherapy induces complete tumor regression in ~50% of patients [16]. The introduction of 
novel drugs has aided in the treatment of MM especially in management of elderly patients [3, 
9], and has improved survival rates [17]
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disease. The median age at diagnosis is 69 years for men and 72 years for women (rarely 
occurring before 40) and the median survival is only 5 years [17]. Current chemotherapy 
induces complete tumor regression in about 50% of patients [3, 9]. However, outcome from the 
frontline treatment for MM, autologous hematopoietic stem cell (AHSC) transplant, is usually 
favorable only in younger patients where it increases the rate of complete remission and 
prolongs event-free survival compared with conventional chemotherapy [17]. 
 Pharmacologic interventions are the only option for the majority of patients who are older. A 
MM cure is viewed as distant, but further improvements in survival time are considered 
achievable [16].  
The introduction of novel drugs such as thalidomide, lenalidomide, and bortezomib (Bor) that 
are thought to target specific intracellular pathways and affect cellular interactions with the 
tumor microenvironment, has aided in the treatment of MM, especially in the management of 
elderly patients [19].   
In the last several years, interesting information into the molecular mechanisms of the 
development of MM was achieved for successful therapeutics, such as proteasome inhibitors 
[20]. 
Bor, a boronic acid dipeptide, was the first-in-class proteasome inhibitor approved by the US 
Food and Drug Administration (FDA) for the treatment of relapsed and refractory MM [20, 21]. 
Deregulation of the ubiquitin-proteasome signaling pathway is linked to the etiology of various 
human diseases; therefore, proteasome inhibitors offer great promise as therapeutic agents [20, 
21]. 
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1.2  DRUGS IN MULTIPLE MYELOMA 
Dexamethasone (DEX) is a synthetic element of the glucocorticoid class of steroid.  This drug 
has been used as an anti-inflammatory and immunosuppressant. DEX is more potent than the 
hormones, cortisol and prednisone.  
DEX was used to treat autoimmune conditions, rheumatoid arthritis and other different 
conditions such as brochospasms, and DEX has been used to fight allergic anaphylactic shock. 
Furthermore, DEX has been used as a chemotherapeutic agent in MM and as an adjuvant in 
other cancers to combat some of the side effects of chemotherapy. 
The side effects of DEX are stomach distress, increased stomach ulcers, diabetes mellitus, 
personality changes, osteoporosis, muscle atrophy, and acne. This glucocorticoid steroid is 
excreted mainly in the urine and has a half-life of 36-54 h [15-21]. 
 
Thalidomide (THAL) is an immunomodulatory agent (dioxopiperidin) developed by German 
pharmaceutical company in the 50’s as a possible antidote to nerve toxins and sedative drug to 
combat morning sickness.  It was withdrawn in 1961 due to tetragenicity and neuropathies. 
From 1957 to 1961, this drug caused more than 10,000 birth defects in more the 40 countries.  
The side effects of this drug led to more restricted testing before future drug licensing. 
 In 1994, Dr. Robert D’Amato at Harvard Medical School discovered that thalidomide is a 
potent inhibitor of anti-angiogenic effects. 
THAL use in MM appears to slow down the progression of the disease by halting the 
production of interleukin-6 (IL-6), a key player in the proliferation of MM cells. Furthermore, it 
activates apoptotic pathways and T cells to produce interleukine-2 (IL-2), increasing the 
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activity of natural killer (NK) cells [15-21, 80.  This drug has several side effects such as 
polyneuropathy, fatigue, skin rash, venous thromboembolism (VTE), stroke, and myocardial 
infarction. 
THAL is metabolized in vivo and metabolites are excreted primarily in the urine. The half-life is 
in the order of a few hours [17-29, 80].   
 
Bortezomib (BOR) was originated in 1995 and was originally called MG-341 by ProScript.  
This dug is an N-protected dipeptide (phenylalanine and leucine) with boronic acid [21-29, 77, 
80-82]. The mechanism of this drug is based on the boron atom in bortezomib which binds the 
catalytic site of the proteosome (26S).  
The proteosome in the normal cells regulates protein expression and function by eliminating 
cells that misfolded proteins. This mechanism is extremely important in maintaining cell 
immortality [21-29, 77, 80-82].  This drug reaches its peak in about 30 minutes. BOR levels 
have been measured by proteosome inhibition in peripheral blood mononuclear cells (PBMC).  
This small molecule is the first proteosome inhibitor to be used in humans [21-29, 77, 80-82]. 
Side effects of this drug are the following: peripheral neuropathy, myelosuppression, 
neutropenia, thrombocytopenia, shingles, gastro-intestinal distress and asthenia. This anticancer 
agent has a half-life of 8 to 15 h.   
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1.3 MULTIPLE MYELOMA TARGETED THERAPIES AND TUMOR 
MICROINVIROMENTS 
Figure 1 describes how to prevent drug resistance and improve patient outcome by 
simultaneously targeting MM cells and their microenvironment in the BM [13, 14, 22, 24, 31].  
Adhesion to BM stromal cells is thought to prevent apoptosis, affect transcriptional diversity, 
differentiation of MM cells, and secretion of cytokines, such as IL-6, that promote MM cell 
growth, survival and migration [21-24], and also blocks apoptosis [21-24].   
Many anticancer agents trigger apoptosis that precedes via common downstream effector 
pathways [21-24], and Bor inhibits the proteasome which functions like a “garbage disposal," 
removing abnormal or damaged proteins. Bor causes proteins to accumulate including BAX that 
facilitates apoptosis by blocking Bcl-2. Major cell surface receptors for BM extracellular matrix 
components on MM cells include integrins and the stromal cell, VCAM-1. 
 Molecules such as CD44 isoforms, RHAMM, and CD38 are thought to mediate interactions of 
MM cells with hyaluronan. CXCR4 is an MM cell receptor for stromal-cell derived factor-1 
alpha (SDF-1a) that facilitates adhesion and signals BM homing. Adhesion of MM to BM has 
been targeted in the development of new agents [21-25, 81, 82] such as mAbs to syndecan-1 
(CD138; a heparin sulfate proteoglycan), and lotuzumab, that binds a cell surface glycoprotein, 
CS-1, found on MM cells [20-29, 30-33]. 
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Fig. 1 Novel agents targeting MM and the BM microenvironment (A) cause apoptosis or growth arrest, inhibit 
(B) angiogenesis, (C) MM cell adhesion to BM cells, and (D) cytokine production, or (E) enhance host anti-MM 
immunity. From Hideshima & Anderson (2007). 
 
 
 
FIGURE 1 
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1.4 GALECTIN 
Galectin-3 is a member of the galectin family of animal lectins that is defined based on 
sequence homology within the carbohydrate recognition domain (CRD) and a characteristic 
affinity for b-galactosides (see fig. 2) [25-27]. The amino-terminal domain is critical for the 
multivalent behavior.  
Alone the carboxy-terminal CRD lacks hemagglutination activity and the cooperative binding 
[28-29]. The amino-terminus enables the CRD to cross-link carbohydrate-containing ligands on 
cell surfaces and in the extracellular matrix and, thus, to modulate cell adhesion and signaling 
[27-31].  
Galectin-3 has been found to be involved in multiple cellular processes. Key roles of galectin-3 
in the regulation of the adhesive 
properties of metastatic cancer cells, 
and invasive potentials were originally 
elucidated in pioneering work by Raz 
et al. [32]. Lectins including the 
galectin family [32] have gained 
increasing recognition as potential 
therapeutic targets [25-27, 33-36], and 
specific associations of the expression 
of galectin-3 with cell growth, 
neoplastic transformation, apoptosis, and metastasis have been reported [25-27, 37-38]. In 
Fig. 2 Galectin-3 (top) with CRD to right and N-terminal 
domain (left). Galectin-3 molecules (middle) 
homodimerized through the N-terminal domains. Gal-3C 
(bottom) retains carbohydrate binding but does not form 
multimers. 
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prostate cancer, a small clinical trial of modified citrus pectin, a natural product thought to 
inhibit galectin-3, produced greater doubling times for prostate specific antigen (PSA) levels, 
and the only apparent side effect was abdominal discomfort [47]. 
Galectin-3 is thought to participate in regulation of the inflammatory state of various immune 
cells. Several studies indicate that it plays a novel regulatory role in the B cell compartment [35-
41] including PCs [41]. 
 Hoyer et al. found stage-specific expression during B-cell development [35-43]. Increased 
galectin-3 levels were observed in some of the neoplasms that derive from these cells, 
specifically diffuse large B-cell lymphoma (DLBCL), primary effusion lymphoma (PEL), and 
MM [39-43]. 
Tumor growth and metastasis were virtually eliminated in mice lacking Mgat5, an enzyme 
forming antenna-like oligosaccharides containing lactosamines [43] on molecules such as 
fibronectin recognized by galectin-3 [39-44]. Several tumor antigens express high levels of 
lactosamines, and the affinity of galectin-3 for lactosaminylated oligosaccharides is higher than 
that of most galectins [39-45].  
Silencing expression of galectin-3 in animal models of human cancers including prostate [39-
47, 57] and breast cancers, reduced tumor growth and metastasis.  
Apparently contradictory results were obtained when galectin-3(-/-) mutant mice were crossed 
with genetic mouse models of intestinal cancer, ApcMin and Apc1638N, and a mouse mammary 
gland model, PyMT. Galectin-3 was not a rate-limiting factor in tumorigenicity in these mice 
[44-46]. This likely was due to activity of other members of the galectin family, and the more 
than 1.3 fold up- or down-regulation of the expression of 22 glycosyltransferases [48,49]. 
Gal-3C consists of the 143 carboxy-terminal a.a. residues of human galectin-3. Gal-3C retains 
carbohydrate binding but lacks the N-terminal domain (Fig. 2), and acts as a dominant negative 
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inhibitor competing with endogenous galectin-3 for carbohydrate binding sites and preventing 
its homodimeric cross-linking [50]. Subsequently, the study by Hoyer et al., showed that 
overexpression of Gal-3C in galectin-3-expressing primary effusion lymphoma cells facilitated 
Fas-mediated apoptosis, whereas galectin-3 overexpression in galectin-3-negative Burkitt 
lymphoma cells inhibited Fas-mediated apoptosis [49,50]. 
 
 
2.  AIM OF THE STUDY 
The main hypothesis for this study is to evaluate the potential of Gal-3C, an N-terminally 
truncated form of galectin-3 that is thought to act as a dominant negative inhibitor, for the 
treatment of multiple myeloma (MM). 
3. RESEARCH DESIGN AND METHODS 
3.1 Experimental Design.   
These in vitro and in vivo models investigated the presence of Galectin 3C expression in 9 
human MM cell lines and the capacity of Galectin 3C to inhibit proliferation of these MM cell 
lines. In addition, the capacity of Galectin 3C inhibition of chemotaxis of the U266 MM cell 
line was tested. 
An adeno-associated virus (AAV) and green fluorescence protein (GFP) AAV/GFP virus stock 
was generated and tested to infect the U266 cell line. The infection was confirmed by 
immunofluorescence (IF) labeling, (RT-PCR) and cytofluorimetric analysis (FACs). The single 
components of Bortezomib and Galectin 3C, singularly were tested, and the combination of 
both in the U266 MM mouse model non-obese diabetic /severe combined immunodeficiency 
(NOD/SCID). The results were analyzed by immunohistochemistry (IHC), RT-PCR, Enzyme-
Linked Immunosorbent Assay (ELISA) and Dot Blot. The tumor expression was tested by 
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human immunoglobulin (Ig) IgE, Igλ and A-kinase anchor proteins-4 (AKAP-4) [73]. Further, 
the synergistic effects of Bortezomib and Gal-3C were tested for their ability to inhibit 
endothelial cell migration and angiogenesis. Moreover, flow-cytometry analysis was used to 
observe if Gal-3C impaired nuclear factor-kappa-B (NF-KB) activation induced by Bortezomib 
in U266 [58]. 
3.2 Animals 
Six-week-old female NOD.CB17-Prkdcscid/J (NOD/SCID) mice [72] purchased from the 
Jackson Laboratory (Bar Harbor, ME, USA) were used. Treatment and care were in accordance 
with the Institutional Guidelines and the Animal Welfare Assurance Act. [51,72]. 
 
3.3 Cells and media.  
 Human MM cell lines RPMI-8226, U266 (American Type Culture Collection, VA, USA), 
ARP-1, ARK-B, (gifts from J. Epstein, University of Arkansas for Medical Sciences, Little 
Rock, AR, USA) were used. The MM cell lines MM.1S and MM.1RL were generously 
provided by Dr. Steven T. Rosen (Northwestern University, Evanston, IL, USA) and the NCI-
H929 cell line was donated by Dr. Steven D. Rosen (University of California, San Francisco, 
CA, USA). The 8226/Dox and 8226/LR-5 cell lines were kindly provided by Dr. William S. 
Dalton of the H. Lee Moffitt Cancer Center and Research Institute (Tampa, FL, USA). All MM 
cells were cultured in Roswell Park Memorial Institute medium-1640 (RPMI-1640 medium), 
and supplemented with 10% fetal bovine serum (FBS) in 5% CO2 at 37°C. The 8226/Dox cells 
were cultured with 40 nM doxorubicin (Sigma-Aldrich, St. Louis, MO, USA). The 8226/LR-5 
cells were cultured in media containing 5 mM mephalan (Sigma-Aldrich). 8226/Dox and 
8226/LR-5 cells were maintained in drug-free medium for 1 week prior to drug sensitivity 
assays. 
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Human umbilical cord vascular endothelial cells (HUVEC), (American Type Culture 
Collection, VA, USA) were maintained in Endothelial Cell Growth Medium (EGM-2 medium) 
(Lonza, Houston, TX, USA) and were used within 10 sub-culturing passages [72].  
 
3.4 SDS-PAGE and Immunoblot. 
Flasks of MM cells were harvested, lysed by freezing, and the proteins extracted with M-PER 
protein buffer (Thermo, Rockford, IL) using Protease Inhibitor Cocktail (Sigma-Aldrich). 
Protein concentration was determined with the Bio-Rad Protein Assay (Hercules, CA), and 
equal amounts of each sample were resolved by 4-12% Bis-Tris PAGE (Invitrogen) after 
heating (70°C, 10 min) in sample buffer. 
Proteins were electrotransferred onto nitrocellulose, efficiency confirmed by reversible staining 
with Ponceau S (Sigma-Aldrich), and the blot incubated with anti-galectin-3 antibody [72] 
(M3/38, Santa Cruz Biotechnology, Santa Cruz, CA), followed by biotin-conjugated anti-rat 
IgG, horseradish peroxidase (HRP)-conjugated streptavidin, and then TMB with membrane 
enhancer (KPL; Mandel, Guelph, Canada)[72]. Pictures were taken with a digital camera [72]. 
 
3.5 Drugs and mini-pumps.  
Bortezomib (Bor) was acquired from Millennium Pharmaceuticals (Cambridge, MA, USA). 
Gal-3C was used as previously described [72]. Doxorubicin and mephalan were purchased from 
Sigma-Aldrich (St.Louis, MO, USA). The 200 ml mini-osmotic pumps are specifically built to 
deliver 0.5 mL/h were purchased from DURECT Corporation (Cupertino, CA, USA) [72]. 
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3.6 Cell proliferation assays.  
Cell proliferation was assessed by quantification of ATP metabolism by viable cells (ViaLight 
Plus, Lonza, Walkersville, MD). In brief, myeloma cells were seeded (8,000 per well) in growth 
media and, while HUVEC cells were seeded (10,000/well) in 50ml EGM-2 in 96 well plates. 
The proliferation assay was assessed after 48 h. Aliquots of Gal-3C (dialyzed to remove 
lactose), thalidomide, Dex, Bor, doxorubicin, or controls, which were vehicle-only, were added 
to samples. Analysis was with a Berthold illuminometer (see details in Mirandola et al., 2011) 
[72]. 
 
3.7  Chemotaxis assays.  
U266 cells (400 x 103/well) were plated in 100-ml culture media with and without Gal-3C (0, 
0.4, 2.0, 10, and 20 mg/ml) in 24-well transwell (8-µm pores) inserts. Media (600 ml) with B-
cell chemoattractant stromal cell-derived factor (SDF)-1a (100 ng/ml; R&D Systems) was 
added to the bottom chamber. After 4 h, U266 cells in the bottom chamber were quantified on 
FACScan flow cytometer (2 min acquisition, 200 ms resolution) [72].  
A similar procedure was used for HUVEC cells was preformed as reported in Leonardo et al., 
2011 [72]. 
EGM-2 alone was used a negative control. Subsequent to 16-h incubation, cells were detached 
from the upper chamber, and migrated cells were pictured on the lower side of the filter after 
fixing and staining with 30% methanol + 10% acetic and 0.1% Coomassie Brilliant Blue.  
Following several washing in filtered water, the transwell was air-dried. Pictures were taken 
with an inverted X71 microscope (Olympus America Inc., PA, USA).  
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3.8 Generating AAV/GFP genome and virus stocks.  
The adeno-associated virus/green fluorescent protein (AAV/GFP) genome was designed as 
previously described in Mirandola et al., 2011 [72]. Virus stocks of AAV/GFP were generated 
using complementary plasmids in s96-0.8 plus a helper virus [72] using HEK293 cells.  
Subsequently, lysates of HEK293 cells as a mock and HEK293 cells infected. Following the 
generation of the virus stock and measuring the virus by real-time PCR [72], on an ABI [72, 
102]. 
 
3.9 Testing Gal-3C and Bor in NOD/SCID mouse model of MM.  
U266 cells were washed once in PBS (Sigma-Aldrich, St. Louis, MO, USA), counted, prior to 
injection [72]. U266 cells (1 x 107) were injected subcutaneously into the abdomen of naive 
NOD/SCID mice. The tumor masses were measured weekly with a pair of calipers. The 
formula: width 2x length x 0.5, where width is the smallest dimension [72] was used for tumor 
volume calculations. 
Mice were divided in four groups (groups #1-4).  
Group #1 Control group was inserted subcutaneously an implanted a 200-ml mini-osmotic 
pump with PBS.   
Group #2 received Gal-3C (30 mg/d/mouse) of a total of 500 µg via a 200-ml mini-osmotic 
pump implanted abdominally over a 16-day period.  
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Group #3 received six doses of 15 mg Bor in 50-ul injections via the tail vein on days 1-2, 8-9, 
and 15-16 for a total of 90 mg.  
Group #4 received Gal-3C (30 mg/d/mouse) via mini-pump for a total dose of 500 mg plus a 
total 90mg Bor in 21 days. Mice where sacrificed at day 35 by anesthesia and cervical 
dislocation, and a post-mortem examination were conducted on the whole animals and dissected 
organs [72].   
 
3.10 Real-time PCR.  
Total ribonucleic acid (RNA) was extracted from the U266 cells, and tissue cells from the 
tumors, spleen, kidney, stomach, heart, lung and liver by means of a Trizol-reagent (Sigma-
Aldrich, St. Louis, MO, USA) and isolated with the Oligotex mRNA Mini Kit (QIAGEN, 
Valencia, CA, USA), after deoxyribonuclease enzyme (DNase) I digestion. First-strand 
complementary deoxyribonucleic acid (cDNA) synthesis was performed using oligo (dT) 15 
primers. PCR primers were as follows: 5'-GCGTACTCTGATACTACAATGATG-3' and 5'-
GGG GTTTTGGGTAAAGTCA-3' for AKAP4; and 5- CGGTCGCCACCATGGTGAGC-3’ 
and 5’-GAGCCGTACCTGCTCGACATG-3’ for GFP. The sizes of the primers were amplified 
for AKAP4 to 1100 base pairs (bp) and for GFP to 730 bp, respectively. The positive controls 
were the cDNA of the U266 cells, and the negative controls were the PCR reaction mixture with 
water in place of the cDNA. RNA integrity in each sample was checked by amplification of a β-
actin gene segment [72].  
 
3.11 Flow cytometric analysis.  
FACs analyses were performed for AKAP-4, human IgE, IgG, (heavy chain) k, and λ light 
chains, as previously described [72]. Briefly, cells from liver, blood, U266, and tumor masses 
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were broken up into single cells suspensions in RT as described in Mirandola et al., 2011. 
Single cell suspensions were located into 250-ml flasks containing 3-ml of an enzyme solution 
that consisted of 0.14% collagenase type I (Sigma-Aldrich, St. Louis, MO, USA) and 0.01% 
DNase (2000 kU/mg of tissue; Sigma-Aldrich, St. Louis, MO, USA) in RPMI 1640.  The 
tissues were filtered by a 150-mm pore-size nylon and washed twice in RPMI 1640 
supplemented with 10% FBS and penicillin/streptomycin. 
Cells were incubated with monoclonal antibodies raised against human Ig, AKAP-4 and NF-kB. 
or isotype matching antibodies (BD Biosciences, CA, USA) as negative controls [72]. Analysis 
was performed using a fluorescence-activated cell scanner (BD Biosciences). 
 
3.12 ELISA for human AKAP-4, IgG, E, k, and λ light chain.   
A direct ELISA was performed to measure the levels of human AKAP-4, IgG, IgE, k, and λ 
light chain levels as reported [51, 72]. Antibodies for immunoglobulins were purchased from 
BD Biosciences. The anti AKAP-4 antibody was from Santa Cruz Biotechnology. Signal 
intensity was measured on a Victor 2 multimodal microplate reader (PerkinElmer, MA, USA) at 
450 nm. All samples were run in triplicates [72,73]. 
 
3.13 Tubule formation assay.  
Tubule formation assay was used to measure angiogenesis in vitro and performed as described 
[52,72].  Briefly, growth factor–reduced Matrigel (Becton Dickinson, NJ, USA) was allowed to 
polymerize in the presence of 30 ng/mL recombinant basic fibroblastic growth factor (bFGF; 
R&D Systems MN, USA) for 1 h at 37°C (50 uL/well). HUVEC (5,000/well), serum-starved for 
2 h prior to trypsinization, resuspended in 200 µL of serum-free EGM-2 supplemented with 
20% V/V conditioned medium obtained after 48-h U266 treatment with 10 µg/mL Gal-3C, 5 
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nM BOR, 10 µg/mL Gal-3C + 5 nM BOR, or 0.6% V/V PBS (Gal-3C and BOR vehicle) as a 
control. The positive control was EGM-2 with 20 ng/mL VEGF (R&D Systems MN, USA), 
while the negative control was EGM-2 alone. Cells were seeded onto the polymerized Matrigel 
and incubated for 16 h at 37°C with 5% CO2 to allow tubule formation. The assays were run in 
triplicate and pictures were taken with an inverted X71 microscope (Olympus America Inc., PA, 
USA) [72]. 
  
3.14 ELISA for VEGF and bFGF. 
An ELISA was performed to measure the levels of VEGF and bFGF in media from U266 cells 
treated for 16 h with 10 µg/mL Gal-3C, 5 nM Bor, or 10 µg/mL Gal-3C with 5 nM Bor, or 
control media with PBS only. The levels of VEGF and bFGF were extrapolated using standard 
curves obtained by analysis of 10-fold serial dilutions (0-1,000 ng/mL) of purified recombinant 
proteins (Abcam, MA, USA). 
Subsequently, plates were washed twice with PBS+0.025% V/V Tween-20 (300 µL/well) and 
incubated for 1 h at RT with anti-mouse or anti-rabbit HRP-labeled secondary antibodies (0.2 
µg/mL in PBS, 50 µL/well Abcam, MA, USA). The plates were washed 3 times with 
PBS+0.025% V/V Tween-20 (300 µL/well), and then the TMB colorimetric substrate (Thermo 
Fisher Scientific, IL, USA) was added and absorbance was measured at 405 nm (0.1s) after 5 
minutes on a Victor 2 multimodal microplate reader (PerkinElmer, MA, USA) at 450 nm. All 
samples were run in triplicates [72]. 
 
3.15 Statistical analysis.   
All of the data was expressed as mean values ± 95% confidence interval. Results were analyzed 
using GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego, CA). 
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Univariate analysis was performed through a Student t test as required for parametric variables. 
A p value of less than 0.05 was considered statistically significant. Statistical analysis for tumor 
size was performed through one-way ANOVA test and a Tukey post-test was used to analyze 
the mean tumor volumes with a 95% confidence interval [72]. 
 
3.16 Immunohistochemistry.  
The tissue array was baked following the company’s instructions (DAKO, Carpinteria, CA, 
USA) at 60 ºC. After 15 minutes incubation in a 3% H2O2 solution, it was exposed at room 
temperature (RT) for 45 minutes to the anti-Akap-4 primary antibody (1:100 dilution in 
PBS/BSA 0.1%). After washing, sections were incubated for 30 minutes at RT with DAKO 
Envision system (DAKO, Carpinteria, CA, USA), followed by 5 minutes dark incubation with 
the DAB system (DAKO). Tissues were counter-stained with hematoxylin (Fisher Scientific, 
Pittsburg, PA, USA) and results were evaluated by light microscope (Leica DMLA, USA). 
Pictures were taken at 20X, 40X and 63X magnifications and analyzed by imaging software. 
[72, 73] 
 
3.17 Immunocytochemistry and immunofluorescence. 
 MM plasma cells were spun in a cytospin column in the amount of 5x104-105 cells per slide. 
After fixation with SlideRite (Fisher, USA) and overnight air drying, each sample was 
permeabilized (P) in a 0.1% Triton X-100 sodium citrate buffer, diluted in PBS, for 15 minutes 
at 4°C or left not permeabilized (NP). For immunocytochemistry, cells were exposed to the anti-
Akap-4 primary antibody (1:100 dilution in PBS/BSA 0.1%), and then incubated for 30 minutes 
with the Envision System (DAKO) and 5 minutes with DAB (DAKO). The 
immunocytochemical reaction was observed using a light microscope. Pictures were taken at 
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40X and 100X objective magnifications and analyzed by imaging software. For 
immunofluorescence, cells were incubated overnight in a wet chamber at 4°C with anti-Akap-4 
primary antibody (1:100 dilution in PBS/BSA 0.1%) and with PE conjugated rabbit IgG 
secondary antibody (1:500 dilution) (Abcam, USA). Results were analyzed by inverted 
fluorescence microscope (Olympus IX71 inverted microscope equipped with laser), pictures 
were taken at 20X and 40X objective magnifications, and analyzed by Flow-view software 
[72,73]. 
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4. RESULTS  
4.1 Galectin-3 expression in MM cell lines 
Nine MM cells: MM-1S, MM-1RL, NCI-H929, RPMI-8226, 8226/Dox-40, 8226/LR-5, ARP-1, 
ARK-B, and U266 were evaluated by Western blot to identify galectin-3 protein. 
 Figure 4.1 shows that all of the cell lines have galectin-3 protein (~30 kDa). The levels of 
expression of galectin-3 in the nine MM cells are heterogenic; only U266 and NCI-H929 
expressed the highest levels [72]. 
The M3/38 anti-galectin-3 antibody stained three other bands. Earlier studies indicate that this 
antibody binds the N-terminal domain of the full-length protein [48-55].  Galectin-3 is digested 
by mammalian metalloproteinases (MMPs) including MMP-2, -9, and -13 that primarily cleave 
the Ala62 –Tyr63 bond yielding a fragment of ~22 kDa containing the CRD and an N-terminal 
fragment [48-55]. The Gly32-Ala33 bond is an interchange site for cleavage by MMPs that 
yields a 27 kDa fragment including the CRD [53-54]. 
An additional band that comes out at approximately 75 kDa in size is of similar intensity in each 
sample. Galectin-3 can form non-covalent homodimers and higher order multimers by mediated 
binding of its N-terminal domain [55, 56]. Previous to electrophoresis, the samples were heated 
at 70 °C rather than boiled, thus, it is also possible that the 75 kDa bands were composed of 
non-covalent homodimers of galectin-3. Transglutamination should not be affected by 
reduction, but it is unlikely that disulfide bonds survived the treatment of the samples with the 
reducing agent, 2-mercaptoethanol [72]. 
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FIGURE 4. 1 
 
 
 
 
Figure 4.1. Galectin-3 expression levels in MM cell lines and effects of galectin-3 inhibition 
in vitro. 
 
(a) The protein lysates of MM cells are: MM-1S; 2 MM-1RL; 3 NCI-H929; 4 RPMI-8226; 5 
Dox-40; 6 LR-5; 7 ARP-1; 8 ARB-B; 9 U266. Protein fractions were analyzed by immunoblot 
to locate galectin-3 (30 kDa) (see arrow). (b) Shows the graph results from proliferation assays 
of MM-1S, MM-RL, NCI-H929, and RMPI-8266 and (c) ARP-1, ARK-B, U266, and 8226/Dox 
cells to 0.5, 1, 2, or 4 µg/ml Gal-3C compared to the control (48 h).  Low proliferation when 
MM cell lines were treated with Gal-3C (defined as P<0.05; t-test) after 48 h. (d) Proliferation 
assays with MM-1S, MM-RL, NCI-H929, and U266 with different doses (0.4, 2, 10,or 20 µg/ml 
Gal-3C versus control wells over 24 h). Significant decrease (P<0.01) in proliferation of MM-
1S, NCI-H929, and U266 cells in response to Gal-3C after 24 h. Error bars are ± S.D [72] 
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4.2 Gal-3C inhibits chemotaxis of U266 cells. 
The adding together of Gal-3C to the media with U266 cells in the top chambers of bicameral 
transwell chambers (Figure 4.2) (P<0.001 for all Gal-3C treatments versus controls) decreased 
the migration of the cells into the bottom chamber containing SDF-1α, a potent lymphocyte 
chemotactic factor [56, 57, 60, 62, 64, 72]. The percentage of inhibition improved by more than 
70% using 2.0 µg/ml Gal-3C in contrast to a 0.4 µg/ml. Nevertheless, mounting the 
concentration to 10 and 20 µg/ml generated only a little higher percentage of inhibition in 
contrast to 2.0 µg/ml [72]. 
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FIGURE 4.2 
 
Figure 4.2. Gal-3C inhibits the chemotaxis and invasion of U266 MM cells. 
 
(a) Chemotaxis of U266 was significantly reduced by Gal-3C (0.4, 2, 10, or 20 µg/ml) in 
response to SDF-1α (100 ng/ml). Error bars are ± S.D. and sextuplicate data points are 
represented (ANOVA with Tukey test P<0.001 for all, compared to controls).  
(b)  Significant reduction in the invasion activity of U266 by Gal-3C and Bor. Experiments 
were repeated three times. Error bars represent ±SD [72]. 
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4.3 Generation and testing of AAV/GFP virus stocks 
A map of the AAV/GFP vector is shown in Figure 4.3.  XbaI and NotI were used as a restriction 
sites to insert the GFP gene downstream of the p5 promoter. Figure 4.3B illustrates the 
identification of AAV/GFP by restriction enzyme analysis. XbaI and NotI enzymes cut GFP 
from AAV/GFP.  The titers of virus stocks were determined by real-time PCR (Figure 4.3B) to 
be 108 encapsulated genomes (eg). Subsequent to the generation of the AAV/GFP virus stock, 
the infection of U266 cells was analyzed.  U266 cells were infected with AAV/GFP, and 
confirmed the infection by immunofluorescence labeling, RT-PCR, and cytofluorimetric 
analysis (Figs. 4.3C and 4.3D) [72,102].  
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FIGURE 4. 3 
 
 
Figure 4.3. Viral vectors and analysis of infection. 
 
(A) A map of the AAV/GFP. Xba I and Not I were used as restriction enzymes to insert the 
GFP coding sequence. (B) The ligation of AAV genome and GFP. The GFP insert was 
extracted from AAV/GFP by Xba I and not I (lane 2). (C) Quantification of virus titers by real-
time PCR. (D) Identification of U266 cells transduced with AAV/GFP by flow cytometry. (E) 
RT-PCR for GFP expression in transduced U266 cells. M: Marker, 1: AAV/GFP plasmid, 2: No 
RT 3: No template, 4: U266 cells transfected with AAV/GFP. (F) Photo of U266 cells showing 
fluorescence of AAV/GFP-transduced U266 cells [72]. 
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4.4 Gal-3C and Bor synergistically inhibited endothelial cell migration 
Chemotaxis assays were performed to assess the effects of Gal-3C on MM cell-induced 
migration of endothelial cells, using a Transwell®-based platform. U266 cells were cultured in 
media in the presence of 10 µg/mL Gal-3C, 5 nM Bor, the combined treatment, or control 
(PBS)-only, following 48 h of conditioned media (c.m.) produced by U266 cells. The U266 
were used in different treatments with 20% diluted EBM-2 medium and human umbilical cord 
vascular endothelial (HUVEC) cells. Results of a 16-h migration assay are shown in Figure 4.4a 
and 4.4b. [68,72]. Matrigel™-based tubule formation assay was performed to assess the effects 
of diverse treatments on the ability of U266 cells to stimulate angiogenesis [68-72, 87]. Results 
show that treatment with Gal-3C or Bor only, and in combination, almost completely blocked 
the potential of U266 cells for induction of angiogenesis (Figure 4.4.c) [72, 74]. 
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FIGURE 4.4 
 
 
 
Figure 4.4 Vascular endothelial cell migration and tubule formation. 
 
(a) Migration index graph [72]. Mean migration indices (error bars are ± SD) were expressed as 
the number of cells migrated in the presence of the indicated stimuli divided by the number of 
cells migrated in the presence of EBM-2 alone [72]. (b) Representative pictures of the filters. 
(c) Representative pictures of tubule formation with different conditions [72]. 
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4.5 Gal-3C did not affect endothelial cell viability. 
To establish if the effects of Gal-3C alone or in combination with Bor on vascular endothelial 
cell migration or secretion were due to reduced cell viability, the HUVEC cells were treated 
with Gal-3C, Bor, or both agents for 48 h.  The viability for U266 was measured. Since at the 
highest concentrations, Gal-3C had a low effect on HUVEC viability and Bor alone showed an 
impressive inhibition, Gal-3C (2 µg/ml) and Bor (1 nM) were used for the chemotaxis assays. 
Results were run in triplicate, see figure 4.5 [72]. 
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FIGURE 4.5 
 
 
 
Figure 4.5. Vascular endothelial cell viability assay. 
 
Representative of viability of a U266 cells assay.  Experiments were run in triplicate and 
displayed as percentage of control (untreated) cells. The graphs show mean values and error 
bars represent ± SD. **ANOVA Tukey's post test P<0.01. n.s. = not significant [72]. 
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 4.6 Gal-3C and Bor reduced ανβ3 integrin clustering in HUVEC cells 
To assess the effects of the ability of U266 cells to provoke integrin engagement on endothelial 
cells, HUVEC cells were incubated with c.m. produced by U266 cells cultured in 10 µg/mL 
Gal-3C, 5 nM Bor, or the combination for 48 h.  Pictures were taken by a confocal (see Figure 
4.6). Figure 4.6 show that Gal-3C and Bor, in combination, blocked the development of clusters 
of ανβ3 integrins. Cluster of ανβ3 integrins were detected only in control wells. [72, 93-97,100, 
101]. 
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FIGURE 4.6 
 
 
 
 
Figure 4.6.  ανβ3 integrin clustering assay. 
 
Representative pictures of HUVEC cells were fixed and stained with anti-αvβ3 antibody. 
Integrin clusters are evidenced as high-density spots in the HUVEC treated with U266 c.m. (I). 
HUVEC cells treated with different conditions showed less integrin cluster represented by the 
expression of spots as Gal-3C (II) Bor (III) or Gal-3C+Bor (IV). HUVEC cells treated with 
EGM-2 medium alone showed no clusters (V). The figure shows representative 
photomicrographs obtained by confocal microscopy (60X magnification) from three 
independent experiments [72]. 
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4.7 Gal-3C and Bor inhibited secretion of VEGF and bFGF by U266 MM cells. 
ELISA was carried out to determine the levels of VEGF and bFGF in media from U266 cells 
treated with 10 µg/mL Gal-3C, 5 nM Bor, Gal-3C with Bor, or control media with vehicle 
(PBS) only, for 16 h (Figure 4.7) [72, 87]. 
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FIGURE 4.7 
 
Figure 4.7. Molecular effects of Gal-3C and Bor on U266 cells. 
Representative ELISA after 48 h for the measurement of VEGF and bFGF is shown. 
Histograms represent mean values of 3 independent experiments. Error bars indicate ± SD. 
Statistical analysis was performed through one-way ANOVA and Tukey's post-test: **P<0.01; 
***P<0.001 [72]. 
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4.8 Growth of U266 tumors was inhibited by Gal-3C alone, and Gal-3C with Bor 
 
To determine the U266 MM model in the NOD/SCID mice, the treated mice were injected with  
Gal-3C, Bor, and combination of Gal-3C and Bor (Figure 4.8a). In figure 4.8b, the tumor 
volume was measured with calipers once weekly is shown.  
In the group of mice treated with Bor, the tumor volume was less than in the untreated group 
from d 28 through d 35 (unpaired t test P<0.001), whereas the group of mice treated with Gal-
3C and Bor+Gal-3C showed smaller tumor masses than the control group (82% and 61%, 
respectively) (unpaired t test P<0.001).  
The groups receiving the combination of Gal-3C with Bor had less tumor mass of the groups 
treated with Bor (or with Gal-3C) starting on d 21 (unpaired t test P<0.001).  
The mice that were treated with Gal-3C generated fewer and smaller tumor masses versus the 
mice treated with Bor, starting on d 21 (unpaired t test P<0.001), with a mean difference 
between the two of 4.431±1.494 mm3, through d 35 when the mean difference was 31.54±4.379 
mm3 (unpaired t test P<0.001).  
The combination therapy had the greatest effect at day 35, with a reduction of 94% in the mean 
tumor volume, versus the untreated group (unpaired t test P<0.001) [72]. 
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FIGURE 4.8 
 
 
 
Figure 4.8. Experimental design and outcome of Gal-3C treatment in NOD/SCID MM 
xenografts. 
 
(a) Schedule of tumor challenge, drug administration, and sample collections. (b) Graph of 
tumor masses showing Gal-3C with different treatments (untreated, Bor, Gal-3C and Bor plus 
Gal 3-C) [72]. 
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4.9 Analyses of AKAP-4 and GFP expression. 
To analyze the mRNA of the AKAP-4 and GFP by RT-PCR, specimens of the subcutaneous 
tumors (see Figure 4.9) were collected. These results showed the mRNA expression of both 
GFP and AKAP-4 and established that the tumor masses originated from U266 cells (Figure 
4.9) [72]. 
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FIGURE 4.9 
 
 
 
 
Figure 4.9. Analysis of AKAP-4 and GFP expression. 
Depiction of RT-PCR showed the expression of AKAP-4 and GFP in different treatments (PBS, 
Bor, Gal-3C, and Bor plus Gal-3C) [72]. 
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4. 10 ELISA for human immunoglobulins and AKAP-4 in mouse serum. 
AKAP-4 also was identified in the sera of tumor-bearing mice (Figure 4.10 bottom panel).  The 
increased AKAP-4 levels were associated with tumor growth. The serum starting in the vehicle-
only group on d 21 was analyzed. At 35 d after injection the level of AKAP-4 in the sera from 
the combination therapy (Gal-3C plus Bor) group was less than the control group [72]. 
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FIGURE 4.10 
 
 
Figure 4.10. ELISA for human immunoglobulins and AKAP-4 in mouse serum. 
 
ELISA measured the levels of immunoglobulins and AKAP-4. Each graph is representative of 
three experiments with samples analyzed in triplicates, and the error bars represent ± SD [72]. 
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4.11 Flow cytometric analyses of the expression of IgE and IgG.  
 
 
FACs established the expression of IgE and Igλ by the tumors (Figure 4.11). The expression of 
IgE, Igλ and AKAP-4 were higher in the tumors of the control group. These results are similar 
to the results to the previous analysis [72]. 
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FIGURE 4.11 
 
 
 
 
 
Figure 4.11. Flow cytometric analyses of the expression of IgE, IgG, Igκ, Igλ, and AKAP-
4. 
 
FACs analyses of the expression of immunoglobulins and AKAP-4. Single cell suspensions 
were obtained from liver, blood and tumor masses of different groups of mice treated with 
different conditions (PBS, Gal-3C, Bor, and Bor plus Gal-3C) [72]. 
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4. 12 Molecular effects of Gal-3C and BOR on U266 cells. 
 After 48 h in the presence of indicated treatments, the levels of active NF-kB (serine 529 
phosphorylated p65 subunit) were evaluated in U266 cells by flow-cytometry. Left, dot-plot; 
right, distribution of fluorescence intensity (filled gray histogram: control; bold black line: Gal-
3C alone; gray line: BOR alone; thin black line: Gal-3C + BOR). c) Possible mechanisms of 
Gal-3C and BOR interaction in MM cells (see figure 4.12). Inactive NF-kB is located in the 
cytoplasm where it forms complexes with IKBα. Upon IKK-mediated phosphorylation, IKBα 
dissociates from NF-kB complex (p50 and p65 proteins). Free NF-kB is then phosphorylated on 
serine 529 of the p65 subunit and finally enters the nucleus where it regulates the transcription 
of target genes. It is known that administration of BOR administration to MM cells in culture 
activates the canonical NF-kB pathway by the inhibitor of nuclear factor kappa-kinase IKKβ 
phosphorylation, while galectin-3 promotes the activation of IKKα, also resulting in induction 
of NF-kB pathway.  
Therefore, the contemporary administration of IKK inhibitors or Gal-3C with BOR is expected 
to have synergistic effects on MM cytotoxicity [76-85, 100]. 
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FIGURE 4.12 
 
 
 
 
Figure 4.12. Molecular effects of Gal-3C and BOR on U266 cells. 
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 5.  Discussion  
The standard treatment for MM is based on high-dose chemotherapy, radiotherapy, and 
autologous hematopoietic stem cell transplantation.  MM is still not well-understood and 
remains a fatal hematological disease. 
Bor was approved by the FDA in 2003 to treat refractory MM by the FDA [4, 18, 23, 45, 46, 50, 
81, 82].  Remarkably, Bor alone or in combination with thalidomide or lenalidomide, offers up 
to 85% response rates, but more 95% of the patients ultimately relapse [45,46, 50, 56,57].  
In this study, Gal-3C, in single or in combination with Bor, was evaluated in vivo using a 
NOD/SCID mouse model using human MM cells. 
Furthermore the in vitro analysis was not as effective and showed that Gal-3C has a low 
inhibition to the proliferation of all 8 MM cell lines (see Figure 4.1). I hypothesized that the low 
effect in vitro was due to inhibition of galectin-3 [57, 58, 59]. Nevertheless, Gal-3C alone or in 
combination is more effective in vivo. The results show that Gal-3C has anti angiogenesis 
effects in MM.  
Moreover angiogenesis plays a major role between MM cells and the tumor environment [68-
70]. VEGF has been described in the literature [71-74] that is the main mediator of MM-
induced angiogenesis [71-74].  
Galectin-3 has been described by Li WW, et al. to inhibit VEGF-mediated angiogenesis [74].I 
hypothesize that the effects of Gal-3C in vivo inhibits the angiogenesis process produced by the 
engrafted U266 cells. The results show that the combination of Gal-3C and Bor creates 
significantly less HUVEC migration and angiogenesis (Figures 4.3, 4.4) [72]. The single 
treatments inhibited the angiogenesis process but not the migration.  Integrins such as ανβ3 are 
important in the process of angiogenesis [72]. 
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In Figure 4.5, the collective use of Bor and Gal-3C and the single treatment can block ανβ3 
integrin activation [72].  
The ELISA assays showed that single and/or combination (Gal-3C and Bor) diminished the 
ability for the U266 to secrete VEGF. Only when Bor was used alone there was a decline in 
bFGF levels (Figure 4.6). These results indicate that Gal-3C and/or Bor obstruct HUVEC 
migration and in vitro angiogenesis by the down-regulation of VEGF and bFGF [72]. 
The Gal-3C is shown to be more effective in the in vivo model due to the interactions with 
tumor environment. [60-63,72]. Gal-3C inhibited tumor growth in a NOD/SCID mouse model 
of MM to a greater extent than Bor. Combining Gal-3C with Bor caused greater reduction than 
either alone, promising proof-of-concept data that justifies proceeding towards human clinical 
testing.  
Bor is one of the most effective drugs for MM, and is incorporated into front-line care. Bor is 
beneficial in combination therapies [85], but often becomes ineffective due to resistance and 
display of off-target  toxicity [87].  New combination therapies with Bor may facilitate better 
patient outcomes.  
The in vivo activity of Gal-3C in the U266 s.c. NOD/SCID model was largely mediated by 
interactions involving the tumor microenvironment [86] through angiogenesis and inhibition of 
adhesion [87]. The data are supported by recent results of Markowska et al. who showed that 
Gal-3C inhibited VEGF-mediated angiogenesis, and that galectin-3 induces angiogenesis [88].  
Inhibition of U266 cell chemotaxis in response to SDF-1α also demonstrated the potential 
anticancer activity of Gal-3C in human MM. Galectin-3 has been shown to bind to mucin-1 [87-
88], a glycosylated oncoprotein, which is important in tumorigenicity and metastasis of cancers 
[87, 89] including MM [90-93], β1integrins [94-97] that modulate MM adherence to fibronectin 
stimulating transcription of proto-oncogenes [ 98-100], and SDF-1α [101].   The tumor marker, 
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cancer testis antigen (CTA), AKAP-4 (highly expressed in MM cells) [11, 73] was used. The 
ELISA showed that heavy and light chain IgE and AKAP-4 levels were less in treated groups 
versus to the control group on d 21, 28, and 35 (Figure 4.10).  
These results were repeated by a FACs analysis of IgE and Igλ on cells from MM tumors 
(Figure 4.10), confirming the previous data [72,73]. AKAP-4 was previously studied as a tumor 
marker for MM [47].  
The expression of AKAP-4 and GFP was low in the treated group with Gal-3C and Bor, 
confirming the results with IgE and Igλ [72,73]. 
In MM cells specifically, Bor has been shown to induce the canonical NF-κB pathway by 
triggering IKKβ-mediated phosphorylation of IKBα [74-75, 77]. Earlier studies show that 
galectin-3 can stimulate the NF-κB path downstream targeted genes, and that inhibition of 
galectin-3 with modified citrus pectin (GCS-100) [66-76] damages TNF-α provoked initiation 
of NF-κB by obstructing IKKα phosphorylation of MM cells [66, 67-72],  
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5. 1 Conclusion 
In conclusion, the overall goal of this research is the development of a novel human protein, 
Gal-3C, as a treatment for multiple myeloma (MM) that can be administered with other agents 
to facilitate the induction of apoptosis, and anti-angiogenesis effects and to increase the 
percentage of patients who are responsive to therapy, and their survival rate. MM is rarely 
curable despite the introduction of new therapeutic regimens, and more efficacious treatments 
are needed.  
The results present proof-of-principle for the further study of the activity of Gal-3C in MM and 
justify the initiation of a Phase I clinical trial. 
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